Search research articles
Contact Us
Filters
Showing results (131-140 of 178) with videos related to
Page
of 18
Sort By:
Movement Disorders Clinical Practice
|
October 27, 2018
Famotidine, a Histamine H<sub>2</sub> Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study
Tiago A Mestre, Binit B Shah, Barbara S Connolly, et al.
Brain : a Journal of Neurology
|
April 15, 2025
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy
Blas Couto, Shelley L Forrest, Conor Fearon, et al.
JAMA Neurology
|
December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial
Anthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 25, 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
Klaus Seppi, Daniel Weintraub, Miguel Coelho, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 9, 2018
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
Elizabeth F Brigham, Tom H Johnston, Carl Brown, et al.
Movement Disorders Clinical Practice
|
July 26, 2021
An Open-Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia
Susan H Fox, Matthew Swan, Hyder A Jinnah, et al.
Neuropharmacology
|
February 27, 2024
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
Tom H Johnston, Alix M B Lacoste, Paula Ravenscroft, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy
Shelley L Forrest, Sarah S Zaheer, Ain Kim, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 14, 2020
Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial
Tiago A Mestre, Eliza Freitas, Ahmed Basndwah, et al.
Page
of 18
Search research articles
Search
Showing results (131-140 of 178) with videos related to
Sort By:
Page
of 18
Movement Disorders Clinical Practice
|
October 27, 2018
Famotidine, a Histamine H<sub>2</sub> Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study
Tiago A Mestre, Binit B Shah, Barbara S Connolly, et al.
Brain : a Journal of Neurology
|
April 15, 2025
Midbrain cytotoxic T cells as a distinct neuropathological feature of progressive supranuclear palsy
Blas Couto, Shelley L Forrest, Conor Fearon, et al.
JAMA Neurology
|
December 13, 2016
Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial
Anthony H V Schapira, Susan H Fox, Robert A Hauser, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 23, 2010
Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease
Tom H Johnston, Philippe Huot, Susan H Fox, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
October 25, 2011
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease
Klaus Seppi, Daniel Weintraub, Miguel Coelho, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
August 9, 2018
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
Elizabeth F Brigham, Tom H Johnston, Carl Brown, et al.
Movement Disorders Clinical Practice
|
July 26, 2021
An Open-Label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel in Cervical Dystonia
Susan H Fox, Matthew Swan, Hyder A Jinnah, et al.
Neuropharmacology
|
February 27, 2024
Using artificial intelligence to identify drugs for repurposing to treat l-DOPA-induced dyskinesia
Tom H Johnston, Alix M B Lacoste, Paula Ravenscroft, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 8, 2025
Neuroinflammation distinguishes HLA haplotypes in progressive supranuclear palsy
Shelley L Forrest, Sarah S Zaheer, Ain Kim, et al.
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 14, 2020
Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial
Tiago A Mestre, Eliza Freitas, Ahmed Basndwah, et al.
Page
of 18